Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2024
Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World PracticeDebra L Richardson, Julia C F Quintanilha, Natalie Danziger, et al.
Journal for Immunotherapy of Cancer|March 13, 2025
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancerOladapo O Yeku, Minal Barve, Winston W Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2024
Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid TumorsBabar Bashir, Judy S Wang, Gerald Falchook, et al.
JAMA Oncology|December 16, 2017
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical TrialDebra L Richardson, Michael W Sill, Robert L Coleman, et al.
BMC Cancer|March 19, 2025
Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)Daniel Marbach, Jurriaan Brouer-Visser, Laura Brennan, et al.
Clinical Therapeutics|February 29, 2024
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid TumorsGerald Falchook, Amita Patnaik, Debra L Richardson, et al.
British Journal of Cancer|April 8, 2026
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancerYvette Drew, Lucy Gilbert, Alejandro Martinez Bueno, et al.
Cancer Chemotherapy and Pharmacology|December 14, 2024
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)Sarah E Taylor, Sarah Behr, Kristine L Cooper, et al.
Molecular Cancer Therapeutics|August 28, 2020
Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062)Krishnansu S Tewari, Michael W Sill, Bradley J Monk, et al.
Gynecologic Oncology|October 23, 2024
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER studyKan Yonemori, Valentina Boni, Kim Gun Min, et al.
Pageof 7